Atavistik Bio announced it raised a $120 million Series B financing to push two selective allosteric small-molecule programs into clinical proof-of-concept studies: an oral, AKT1-selective allosteric inhibitor for hereditary hemorrhagic telangiectasia (HHT) and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs).
The round was led by Nextech Invest and The Column Group, with participation from existing investor Lux Capital and new investor Regeneron Ventures, the company said. Proceeds will be used to advance both programs through clinical proof-of-concept milestones, with Atavistik anticipating the HHT program will enter the clinic in the first half of 2026.
HHT is a rare, inherited vascular disorder characterized by abnormal blood vessel formation and frequent bleeding that can lead to chronic anemia and organ complications. Atavistik said there are currently no approved therapies for HHT and positioned selective inhibition of AKT1 as a potentially disease-modifying approach, arguing that prior efforts with pan-AKT inhibitors have been limited by tolerability issues such as AKT2-driven hyperglycemia that can constrain chronic dosing.
For MPNs, Atavistik is pursuing a JAK2 V617F mutant-selective strategy aimed at improving on symptom-focused treatment with current non-selective JAK inhibition. The company highlighted the central role of the JAK2 V617F mutation across MPN subtypes and said a mutant-selective inhibitor could potentially reduce mutant allele burden while preserving normal blood cell production regulated by wild-type JAK2.
Atavistik describes itself as a clinical-stage biotech focused on “precision allostery,” leveraging its proprietary AMPS platform to discover and optimize allosteric small molecules designed to achieve strong target selectivity and improved tolerability.
KEY QUOTES:
“We’re thrilled to announce our Series B financing, and grateful for the support of both our existing and new investors. With this capital, we are well-positioned to advance both our HHT and MPN programs through key clinical proof-of-concept milestones, with the HHT program expected to enter the clinic in the first half of 2026. Our precision allostery approach holds tremendous potential to deliver best-in-class therapeutics with superior efficacy and tolerability profiles. Our team is working with tremendous passion and momentum to translate that promise into meaningful outcomes for patients.”
Bryan Stuart, Chief Executive Officer at Atavistik Bio
“We’ve been continually impressed by the exceptional quality of the compounds discovered from Atavistik Bio’s proprietary AMPS™ platform and by the team’s ability to consistently execute against critical milestones. Atavistik Bio’s HHT and MPN programs would represent enormous advancements in the treatment of these respective diseases. We look forward to seeing Atavistik Bio move these programs into the clinic and bring them closer to patients in need.”
John A. Josey, PhD, Atavistik Board Chair
